PR-POSITIVE BREAST CANCER
Clinical trials for PR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new PR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for PR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…
Matched conditions: PR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Early trial of targeted combo for rare breast cancer subtype ends early
Disease control TerminatedThis early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific advanced breast cancer that is hormone receptor-positive, HER2-negative, and has changes in the FGFR gene. The main goal was to find a safe dose by monitoring side effects. …
Matched conditions: PR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated May 06, 2026 16:03 UTC